These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

178 related articles for article (PubMed ID: 15679766)

  • 1. Novel bismuth-metronidazole-tetracycline triple-layer tablet for treatment of Helicobacter pylori.
    Graham DY; Opekun AR; Belson G; El-Zimaity HM; Carlson MR
    Aliment Pharmacol Ther; 2005 Jan; 21(2):165-8. PubMed ID: 15679766
    [TBL] [Abstract][Full Text] [Related]  

  • 2. One-week ranitidine bismuth citrate versus colloidal bismuth subcitrate-based anti-Helicobacter triple therapy: a prospective randomized controlled trial.
    Kung NN; Sung JJ; Yuen NW; Li TH; Ng PW; Lai WM; Lui YH; Lam KN; Choi CH; Leung EM
    Am J Gastroenterol; 1999 Mar; 94(3):721-4. PubMed ID: 10086657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized comparison of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori.
    Laine L; Estrada R; Trujillo M; Emami S
    Am J Gastroenterol; 1997 Dec; 92(12):2213-5. PubMed ID: 9399755
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A single drug for Helicobacter pylori infection: first results with a new bismuth triple monocapsule.
    de Boer WA; van Etten RJ; Schneeberger PM; Tytgat GN
    Am J Gastroenterol; 2000 Mar; 95(3):641-5. PubMed ID: 10710051
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Twice daily (mid-day and evening) quadruple therapy for H. pylori infection in the United States.
    Graham DY; Belson G; Abudayyeh S; Osato MS; Dore MP; El-Zimaity HM
    Dig Liver Dis; 2004 Jun; 36(6):384-7. PubMed ID: 15248377
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pylera for the eradication of Helicobacter pylori infection.
    Saleem A; Qasim A; O'Connor HJ; O'Morain CA
    Expert Rev Anti Infect Ther; 2009 Sep; 7(7):793-9. PubMed ID: 19735221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of ranitidine bismuth citrate, tetracycline and metronidazole with ranitidine bismuth citrate and azithromycin for the eradication of Helicobacter pylori in patients resistant to PPI based triple therapy.
    Altintaş E; Ulu O; Sezgin O; Aydin O; Camdeviren H
    Turk J Gastroenterol; 2004 Jun; 15(2):90-3. PubMed ID: 15334317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Six-day therapy with ranitidine bismuth citrate plus low-dose clarithromycin and tinidazole to cure Helicobacter pylori infection.
    Cammarota G; Cannizzaro O; Cianci R; Gasbarrini A; Pirozzi G; Gasbarrini G
    Hepatogastroenterology; 2000; 47(34):1176-9. PubMed ID: 11020908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients.
    Köksal AS; Parlak E; Filik L; Yolcu OF; Odemiş B; Ulker A; Saşmaz N; Ozden A; Sahin B
    J Gastroenterol Hepatol; 2005 Apr; 20(4):637-42. PubMed ID: 15836716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of bismuth containing quadruple therapy as a first-line treatment option for Helicobacter pylori.
    Uygun A; Kadayifci A; Safali M; Ilgan S; Bagci S
    J Dig Dis; 2007 Nov; 8(4):211-5. PubMed ID: 17970879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Helicobacter pylori eradication with a capsule containing bismuth subcitrate potassium, metronidazole, and tetracycline given with omeprazole versus clarithromycin-based triple therapy: a randomised, open-label, non-inferiority, phase 3 trial.
    Malfertheiner P; Bazzoli F; Delchier JC; Celiñski K; Giguère M; Rivière M; Mégraud F;
    Lancet; 2011 Mar; 377(9769):905-13. PubMed ID: 21345487
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of intragastric acidity on Helicobacter pylori eradication with bismuth-metronidazole-amoxicillin.
    Chang CS; Yang CY; Wong FN; Chen GH; Lien HC; Yeh HZ; Poon SK
    Hepatogastroenterology; 1999; 46(28):2713-7. PubMed ID: 10522070
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Simplified 10-day bismuth triple therapy for cure of Helicobacter pylori infection: experience from clinical practice in a population with a high frequency of metronidazole resistance.
    Lerang F; Moum B; Ragnhildstveit E; Sandvei PK; Tolås P; Whist JE; Henriksen M; Haug JB; Berge T
    Am J Gastroenterol; 1998 Feb; 93(2):212-6. PubMed ID: 9468244
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 7-day rescue therapy with ranitidine bismuth citrate after Helicobacter pylori treatment failure.
    Gisbert JP; Fuentes J; Carpio D; Tito L; Guardiola J; Tomas A; Olivares D; Calvet X
    Aliment Pharmacol Ther; 2005 May; 21(10):1249-53. PubMed ID: 15882246
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Azithromycin for the cure of Helicobacter pylori infection.
    Di Mario F; Dal Bó N; Grassi SA; Rugge M; Cassaro M; Donisi PM; Vianello F; Kusstatscher S; Salandin S; Grasso GA; Ferrana M; Battaglia G
    Am J Gastroenterol; 1996 Feb; 91(2):264-7. PubMed ID: 8607490
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clarithromycin, tetracycline, and bismuth: a new non-metronidazole therapy for Helicobacter pylori infection.
    al-Assi MT; Ramirez FC; Lew GM; Genta RM; Graham DY
    Am J Gastroenterol; 1994 Aug; 89(8):1203-5. PubMed ID: 8053435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Colloidal bismuth subcitrate-based twice-a-day quadruple therapy as primary or salvage therapy for Helicobacter pylori infection.
    Dore MP; Graham DY; Mele R; Marras L; Nieddu S; Manca A; Realdi G
    Am J Gastroenterol; 2002 Apr; 97(4):857-60. PubMed ID: 12003419
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acid suppression with ranitidine plus oral triple therapy improves ulcer healing but not Helicobacter pylori eradication.
    Magalhaes AF; Macedo C; Hauck JR; Carvalhaes A; De Nucci G; Magna LA; Pedrazzoli J
    Hepatogastroenterology; 1998; 45(24):2161-4. PubMed ID: 9951885
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of two management strategies for Helicobacter pylori treatment: clinical study and cost-effectiveness analysis.
    Marko D; Calvet X; Ducons J; Guardiola J; Tito L; Bory F;
    Helicobacter; 2005 Feb; 10(1):22-32. PubMed ID: 15691312
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lansoprazole, levofloxacin and amoxicillin triple therapy vs. quadruple therapy as second-line treatment of resistant Helicobacter pylori infection.
    Wong WM; Gu Q; Chu KM; Yee YK; Fung FM; Tong TS; Chan AO; Lai KC; Chan CK; Wong BC
    Aliment Pharmacol Ther; 2006 Feb; 23(3):421-7. PubMed ID: 16423001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.